Kang In Sook, Choi Donghoon, Ko Young-Guk, Shin Dong-Ho, Kim Jung-Sun, Kim Byeong-Keuk, Hong Myeong-Ki, Jang Yangsoo
Division of Cardiology, Department of Internal Medicine, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Republic of Korea.
Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Clin Hypertens. 2024 Aug 1;30(1):21. doi: 10.1186/s40885-024-00282-9.
The indications, benefits, and outcomes of percutaneous transluminal renal artery intervention (PTRI) remain controversial. The study purpose was to evaluate the long-term outcomes of PTRI in clinical practice.
A retrospective review of 217 subjects (254 renal arteries; mean age, 59.8 years) who underwent PTRI based on medical database.
The most common cause of renal artery stenosis was atherosclerosis in 217 (85.4%), followed by Takayasu arteritis (TA) in 23 (9.1%), fibromuscular dysplasia in five (2.0%) and others in nine (3.5%). Mean follow-up duration was 5.7 ± 3.7 years. The first restenosis rate was 7.5% (n = 19; highest in TA: n = 9, 47.4%) and second restenosis occurred in six arteries (five TAs, one fibromuscular dysplasia). Follow-up blood pressure improved from 142.0/83.5 to 122.8/73.5 mmHg (P < 0.001). There was no change within 5 years' follow-up in estimated glomerular filtration rate (P = 0.44), whereas TA changed from 69.8 ± 20.5 to 84.2 ± 17.9 mL/min/1.73 m² (P = 0.008). Progressive renal dysfunction was related to diabetes mellitus, chronic kidney disease, and peripheral artery obstructive disease on multivariate analysis with hazard ratios (95% confidence intervals) of 2.24 (1.21-4.17), 2.54 (1.33-4.84), and 3.93 (1.97-7.82), respectively.
PTRI was associated with a blood pressure reduction. Despite a higher rate of restenosis, patients with TA showed significant improvement in estimated glomerular filtration rate. Diabetes mellitus, chronic kidney disease, and peripheral artery obstructive disease were related with progressive renal dysfunction after PTRI.
经皮腔内肾动脉介入治疗(PTRI)的适应症、益处及治疗效果仍存在争议。本研究旨在评估临床实践中PTRI的长期治疗效果。
基于医学数据库对217例接受PTRI治疗的患者(254条肾动脉;平均年龄59.8岁)进行回顾性分析。
肾动脉狭窄的最常见病因是动脉粥样硬化,共217例(85.4%),其次是大动脉炎(TA)23例(9.1%),纤维肌性发育异常5例(2.0%),其他病因9例(3.5%)。平均随访时间为5.7±3.7年。首次再狭窄率为7.5%(n = 19;TA中最高:n = 9,47.4%),6条动脉出现二次再狭窄(5条TA,1条纤维肌性发育异常)。随访期间收缩压从142.0/83.5 mmHg降至122.8/73.5 mmHg(P < 0.001)。随访5年内估算肾小球滤过率无变化(P = 0.44),而TA患者的估算肾小球滤过率从69.8±20.5 ml/min/1.73 m²升至84.2±17.9 ml/min/1.73 m²(P = 0.008)。多因素分析显示,进展性肾功能不全与糖尿病、慢性肾脏病及外周动脉阻塞性疾病相关,风险比(95%置信区间)分别为2.24(1.21 - 4.17)、2.54(1.33 - 4.84)和3.93(1.97 - 7.82)。
PTRI可降低血压。尽管再狭窄率较高,但TA患者的估算肾小球滤过率有显著改善。糖尿病、慢性肾脏病及外周动脉阻塞性疾病与PTRI术后进展性肾功能不全相关。